Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | ACKR3 | P25106 | 3/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.46 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | BACE1 | P56817 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4924914 | 0.97 | LMNA (0.49) | LMNASMN1; SMN2GAAALDH1A1ACKR3 | |
| SCHEMBL4923881 | 0.97 | LMNA (0.49) | LMNASMN1; SMN2GAAALDH1A1ACKR3 | |
| SCHEMBL4924890 | 0.93 | SMN1; SMN2 (0.49) | LMNASMN1; SMN2GAAALDH1A1POLB | |
| SCHEMBL4921979 | 0.93 | ALDH1A1 (0.56) | LMNASMN1; SMN2GAAALDH1A1ACKR3 | |
| SCHEMBL4914256 | 0.92 | OPRM1 (0.53) | LMNASMN1; SMN2GAAALDH1A1ACKR3 | |
| SCHEMBL4916484 | 0.90 | SMN1; SMN2 (0.47) | LMNASMN1; SMN2GAAALDH1A1POLB | |
| SCHEMBL4924246 | 0.90 | KDM4E (0.52) | LMNASMN1; SMN2GAAALDH1A1POLB | |
| SCHEMBL4922792 | 0.90 | CCR5 (0.50) | LMNASMN1; SMN2GAAALDH1A1POLB | |
| SCHEMBL4913793 | 0.90 | LMNA (0.48) | LMNASMN1; SMN2GAAALDH1A1POLB | |
| SCHEMBL4916432 | 0.90 | LMNA (0.48) | LMNASMN1; SMN2GAAALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080081824-A1 | Substituted piperidines as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY | 2008-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080081824-A1 | Substituted piperidines as modulators of chemokine receptor activity | CCR1, CCR3, CCR2 | LMNA 2533/4885SMN1; SMN2 3688/4885GAA 4442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.